Skip to main
ARDX

Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx (ARDX) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ardelyx is facing challenges in commercial execution and stiff competition in the biopharmaceutical market, which may affect its stock price. However, the company has a strong product pipeline and revenue growth potential with its FDA-approved drugs and potential expansion into the treatment of other conditions. The recent departure of the Chief Commercial Officer may impact the company's commercial strategy, but ARDX remains on solid financial footing with a strong cash position.

Bears say

Ardelyx is facing negative news as their Chief Commercial Officer, Eric Foster, steps down from his role effective August 28th, which comes after a lackluster second quarter performance and reimbursement headwinds. The company remains on solid footing, but the departure could cause potential disruption and hinder their progress towards their $1 billion peak sales goal for its product Ibsrela. However, the potential for continued prescription data and improved reimbursement timing remains a positive for the company's potential for success.

Ardelyx (ARDX) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardelyx (ARDX) Forecast

Analysts have given Ardelyx (ARDX) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Ardelyx (ARDX) has a Strong Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardelyx (ARDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.